/
Hematology
Myelodysplastic Syndrome
50
Pipeline Programs↗
49
Active Trials↗
69
Companies Involved↗
Myelodysplastic Syndrome is a moderately active landscape with 50 programs across 69 companies. The most active players are Celyad Oncology SA, Amgen, Halia Therapeutics, Inc.. 13 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 122
Phase 213
Phase 313
Approved
No programs
Analysis
Modality Breakdown
94%
Small molecule
46 of 49 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 49 classified programs, each share of the total. Modality classified for 100% of 50 pipeline programs.
Analysis
Trial Status
423
clinical trials
Completed241 · 57%
Terminated73 · 17%
Unknown status38 · 9%
Recruiting27 · 6%
Active, not recruiting17 · 4%
Withdrawn14 · 3%
Other13 · 3%
Clinical Trials
Trial Activity
423 trials
Ascorbate in Myelodysplastic Syndrome
Recruiting·—·Phase 2·NCT07283900·38 enrolled
Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome
Recruiting·—·Phase 1·NCT04999943·40 enrolled
Page 1 of 29
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)